Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity | New England Journal of Medicine (nejm.org)

In two phase 3 trials, tirzepatide significantly reduced the apnea-hypopnea index (AHI) in adults with moderate-to-severe obstructive sleep apnea and obesity. In trial 1, the mean AHI reduction at 52 weeks was −25.3 events/hour with tirzepatide versus −5.3 with placebo (P<0.001); in trial 2, it was −29.3 versus −5.5 (P<0.001). Tirzepatide also improved body weight, hypoxic burden, hsCRP, systolic blood pressure, and patient-reported sleep outcomes. Gastrointestinal side effects were the most common but generally mild to moderate.